|From: rocket (Rep: 208) reply to rocket||Date: 11/14/2017 16:21|
|Forum: Wall Street Hot Shots - Msg #24474 - List PLX msgs ||Thread #673964434 (Rec: 0) |
|Under the terms of the agreement, Protalix has licensed PRX-102 to Chiesi for all markets outside of the United States, and Protalix will receive an upfront payment of $25 million from Chiesi and additional payments of up to $25 million in development costs, capped at $10 million per year. Protalix is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone payments, and tiered royalties ranging from 15% to 35% on net sales. Protalix will continue to be the manufacturer of PRX-102 for clinical development purposes and commercial purposes after marketing approvals. > Re: Gap filled, Re: Positive Opinion for Orphan Designation > Re: .7450 This one ...|
>>>>There are only two lifestyles, righteous or unrighteous. Only one will endure the limits of time.<<<<
>>>>Scars remind us of where we've been, they do not have to dictate where we are going.<<<<
>>>>If there is nothing above us we will be consumed by all that is around us.<<<<
>>>>Once you step out of bounds, then there are no bounds.<<<<
| Reply to rocket - Msg #326 - 11/14/2017 16:21|
Gap filled, Re: Positive Opinion for Orphan Designation > Re: .7450 This one $$$$$$$$$$$$$$$$...
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.